HIGHLIGHTS

1825 Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations

1827 Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma
Florian Castet, Catherine E. Willoughby, Philipp K. Haber, and Josep M. Llovet
See related article, p. 1836

1830 Pressurized Intraperitoneal Aerosol Chemotherapy: The Road from Promise to Proof
Loek A.W. de Jong, Nieltka P. van Erp, and Lana Bijelic
See related article, p. 1875

1833 Morning for Irofulven, What Could be fNER?
Haoyang Jiang and Roger A. Greenberg

CCR Drug Updates

1836 FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma
See related commentary, p. 1827

1842 FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer

RESEARCH BRIEFS: CLINICAL TRIAL BRIEF REPORTS

1855 Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer
Giulia Petroni, Aitziber Buqué, Takahiro Yamazaki, Norma Bloy, Maurizio Di Liberto, Selina Chen-Kiang, Silvia C. Formenti, and Lorenzo Galluzzi

CLINICAL TRIALS: TARGETED THERAPY

1864 Preclinical Evaluation and Phase 1b Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor
David S. Hong, Kathleen N. Moore, Johanna C. Bendell, Daniel D. Karp, Judy S. Wang, Susanna V. Ulahannan, Suzanne Jones, Wenjuan Wu, Gregory P. Donoho, Yan Ding, Andrew Capen, Xuejing Wang, Aimee Bence Lin, and Manish R. Patel
PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases

Guowei Kim, Hon Lyn Tan, Raghav Sundar, Bettina Lieske, Cheng Ean Chee, Jingshan Ho, Asim Shabbir, Maria V. Babak, Wee Han Ang, Boon Cher Goh, Wei Peng Yong, Lingzhi Wang, and Jimmy B.Y. So

See related commentary, p. 1830

Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE)

Simon J. Crabb, Sarah Danson, James W.F. Catto, Syed Hussain, Danna Chan, Denise Dunkley, Nichola Downs, Ellice Marwood, Laura Day, Geoff Saunders, Michelle Light, Amy Whitehead, Deborah Ellis, Naveed Sarwar, Deborah Enting, Alison Birtle, Bernadette Johnson, Robert Huddart, and Gareth Griffiths

Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies

Mina M. Tayari, Helena G. Dos Santos, Deukwoo Kwon, Terrence J. Bradley, Amber Thomassen, Charles Chen, Yvonne Dinh, Aymeric Perez, Arthur Zelent, Lluis Morey, Luisa Cimmino, Ramin Shiekhattar, Ronan T. Swords, and Justin M. Watts

Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors

Kyriakos P. Papadopoulos, Karen Autio, Talia Golan, Konstantin Dobrenkov, Elliot Chartash, Qiusheng Chen, Richard Wnek, and Georgina V. Long

Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma

David W. Andrews, Kevin D. Judy, Charles B. Scott, Samantha Garcia, Larry A. Harshyne, Lawrence Kenyon, Kiran Talekar, Adam Flanders, Kofi-Buaku Atsina, Lyndon Kim, Nina Martinez, Wenyin Shi, Maria Werner-Wasik, Haisong Liu, Mikhail Prosniatk, Mark Curtis, Rhonda Kean, Donald Y. Ye, Emily Bongiorno, Sami Sauma, Mark A. Exley, Kara Pigott, and D. Craig Hooper

Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10

Zev A. Wainberg, Charles S. Fuchs, Josep Tabernero, Kohei Shitara, Kei Muro, Eric Van Cutsem, Yung-Jue Bang, Hyun Cheol Chung, Kensei Yamaguchi, Eniko Varga, Jen-Shi Chen, Daniel Hochhauser, Peter Thuss-Patience, Salah-Eddin Al-Batran, Marcelo Garrido, Uma Kher, Chie-Schin Shih, Sukrut Shah, Pooja Bhagia, and Joseph Chao

PET Imaging of TIGIT Expression on Tumor-Infiltrating Lymphocytes

Travis Shaffer, Arutselvan Natarajan, and Sanjiv S. Gambhir

Diffusion-weighted Imaging Allows for Downgrading MR BI-RADS 4 Lesions in Contrast-enhanced MRI of the Breast to Avoid Unnecessary Biopsy

Paola Clauser, Barbara Krug, Hubert Bickel, Matthias Dietzel, Katja Pinker, Victor-Frederic Neuhaus, Maria Adele Marino, Marco Moschetta, Nicoletta Troiano, Thomas H. Helbich, and Pascal A.T. Baltzer

Changes in Diffuse Optical Tomography Images During Early Stages of Neoadjuvant Chemotherapy Correlate with Tumor Response in Different Breast Cancer Subtypes

Mirella L. Alois, Kevin Kalinsky, Alessandro Marone, Hyun K. Kim, Hua Guo, Hanina Hibshoosh, Mariella Tejada, Katherine D. Crew, Melissa K. Accordino, Meghna S. Trivedi, Dawn L. Hershman, and Andreas H. Hielscher

Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [64Cu]Cu-NOTA-anti-CD8 PET

Veronica L. Nagle, Kelly E. Henry, Charli Ann J. Hertz, Maya S. Graham, Carl Campos, Luis F. Parada, Neeta Pandit-Taskar, Andrea Schietinger, Ingo K. Mellinghoff, and Jason S. Lewis

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)

### TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2074</td>
<td>Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ Specificity and Treatment Resistance</td>
<td>Lir Beck, Michal Harel, Shun Yu, Ettai Markovits, Ben Boursi, Gal Markel, and Tamar Geiger</td>
</tr>
<tr>
<td>2087</td>
<td>Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells</td>
<td>Wenting Pan, Zhouwei Zhang, Hannah Kimball, Fangfang Qu, Kyler Berlind, Konrad H. Stopsack, Gwo-Shu Mary Lee, Toni K. Choueiri, and Philip W. Kantoff</td>
</tr>
<tr>
<td>2100</td>
<td>A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer</td>
<td>Alex Cazes, Oscar Betancourt, Edgar Esparza, Evangeline S. Mose, Dawn Jaquish, Eric Wong, Alexis A. Wascher, Hervé Tiriac, Marco Gymnopoulos, and Andrew M. Lowy</td>
</tr>
</tbody>
</table>

### LETTERS TO THE EDITOR

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2119</td>
<td>Outcomes of Oral Vinorelbine in Progressive Desmoid Fibromatosis—Letter</td>
<td>Chuanxi Zheng, Li Min, and Chongqi Tu</td>
</tr>
</tbody>
</table>

**AC icon indicates AuthorChoice**

For more information please visit www.aacrjournals.org

### ABOUT THE COVER

The cover shows a section of pancreatic cancer precursor lesions in a mouse model of this disease expressing oncogenic Kras and the Sonic Hedgehog ligand. Gomori trichrome stain shows collagen deposition in blue, cell nuclei in dark purple, and cell cytoplasm in pink. For details, see the article by Steele and colleagues on page 2023 of this issue.